Lamuraglia M

ORCID: 0000-0001-8009-0218 · 1 paper in corpus

2024

Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.

Nature communications ·doi:10.1038/s41467-024-45974-w

Most patients with advanced ovarian cancer (AOC) ultimately relapse after platinum-based chemotherapy. Combining bevacizumab, olaparib, and durvalumab likely drives synergistic activity. This open-label phase 2 study (NCT04015739) aimed to …